http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
기회비용 기반 임계값 추정 연구에 대한 체계적 문헌고찰
홍지형 ( Jihyung Hong ),배은영 ( Eun-young Bae ) 한국보건경제정책학회 2022 보건경제와 정책연구 Vol.28 No.2
A cost-effectiveness threshold is required when deciding whether a new healthcare technology is too expensive. There are generally two perspectives on what a cost-effectiveness threshold should reflect. A demand-side approach emphasizes the consumption value of health, whereas a supply-side approach emphasizes the opportunity costs of funding decisions. In recent years, there has been growing attention on the opportunity cost-based threshold, especially with the rise of high-cost healthcare technologies. This study, therefore, conducted a systematic review of studies estimating the opportunity cost-based thresholds. A total of 17 studies were included in this review, of which 14 conducted country-specific analyses. These studies generally estimated the marginal cost per unit of health produced within the health care system. Threshold estimates were relatively lower in the UK, Australia, and other upper-middle-income countries such as China and Colombia than in the United States and Nordic countries, which were well below the GDP per capita. In addition, methodological approaches taken in the included studies were thoroughly reviewed and analyzed to derive methodological implications and insights. These findings, together with the local context and the type of data available, should be fully taken into account when estimating one such threshold in Korea.
권상일(Sangil Kwon),이우석(Wooseok Lee),홍지형(Jihyung Hong),김현근(Hyungeun Kim),명차리(Cha-Lee Myung) 한국자동차공학회 2009 한국자동차공학회 학술대회 및 전시회 Vol.2009 No.11
UN-GRPE Particulate Measurement Programme (PMP) is a collaborative programme operating under the auspices of the UNECE/GRPE Group. Its focus is on the development of a new approach to the measurement of particle in vehicle exhaust emissions, which may be used to replace or to complement the existing mass based system used for regulatory purposes. This paper is the test results of PMP Heavy-Duty Round-Robin during May to June '09 conducted at National Institute of Environmental Research (NIER) in Korea to analyze the repeatability and reproducibility between laboratories. In addition to regulated gaseous emissions, the real time particle emission was simultaneously measured with CPC, and EEPS during the daily protocol described in "UN-GRPE PMP Phase 3: Inter-laboratory Correlation Exercise: Updated Framework and Laboratory Guide for Heavy Duty (HD) Engine Testing" Detailed particle emissions over various engine certification cycles showed that the particle number concentration (#//kWh) was 3.508E+11 (weighted WHTC), 6.087E+10 (WHSC), 4.596E+10 (ETC), and 3.389E+12 (ESC) respectively. Particle mass (g/kWh) was ranged from 0.0011 (WHSC) to 0.0031 (ESC). The repeatability of particle number and mass were reached about 22~107% and 25~73%. The large CoV of particle emissions was ascribed by ETC mode which value 107% and 73%.
경제성평가자료제출생략 트랙으로 진입한 약제에 대한 외국의 치료적 이익 평가 결과 비교
배은영(Eun-Young Bae),차소희(Sohee Cha),임화령(Hwa-Ryeong Lim),이혜재(Hye-Jae Lee),홍지형(Jihyung Hong) 대한약학회 2024 약학회지 Vol.68 No.1
This study assessed the additional health benefits of the drugs listed through the Economic Evaluation Exemption Procedure (EEEP) in Korea. We conducted a comparative review of 32 EEEP drugs listed between May 2015 and July 2022, comparing how they were assessed in France, Germany, and Canada. To collect the data, we reviewed the evaluations conducted by the relevant agency in each country and identified if the additional benefit exists and how significant it is. Additionally, the size of the benefit gains assessed by each agency was categorized as “High” or “Low,” allowing us to evaluate the consistency among these countries. In France, only 38% of the 34 drugs compared demonstrated moderate or higher levels of additional benefit. Germany acknowledged substantial benefit improvement in 27% of the 30 drugs assessed, while 73% showed minor, unquantifiable, or no additional benefits. In Canada, 5 out of 22 cases have been identified as providing significant additional benefit. The level of inter-country consistency in the assessment results from these three countries was somewhat limited. Based on the evaluation results in France, Germany, and Canada, the additional benefits of EEEP drugs over existing treatments were not substantial in many cases. Even though the EEEP was introduced to improve accessibility to high-cost drugs for medical conditions with unmet needs, it is necessary to reconsider whether to allow exceptions for drugs with low therapeutic value.